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Abstract
Background: In 2004, we initiated an inception cohort of patients with recent-onset rheumatoid arthritis (RA).
Hand function was incorporated into evaluations from 2014 onward. The objectives were to examine hand
function in our cohort, compare hand function with function in healthy controls and determine the factors
associated with impaired function.
Methods: From February 2014 to June 2015, 139 patients (97.2 % of the cohort) had disease activity scored
(28 joints, [DAS28]); the Michigan Hand Outcome Questionnaire (MHQ) and Disabilities of the Arm, Shoulder
and Hand Outcome Measure (DASH) were completed, and the tip-, key- and palmar-pinch and grip strengths
were measured. Sixty-nine healthy controls underwent the same evaluations. Ninety-nine patients underwent
a second evaluation one year after their baseline. Descriptive statistics and linear regression models were
used. Patients and controls signed informed consent.
Results: Patients were primarily middle-aged females with a median disease duration of 7 years; 91 patients
had DAS28-remission, and 16, 23, and 9 patients had low, moderate and high disease activity, respectively.
Controls scored better than did patients with (any) disease activity level; remission patients had similar DASH
and key pinch function as did controls with poorer MHQ and both tip and palmar pinch and grip strength.
DAS28 was consistently associated with impaired hand function. Among the patients with a one-year
re-assessment, changes in DAS28 correlated (rho = 0.34 to 0.63) with changes in hand function (p ≤ 0.01
for all comparisons), but there was no correlation with palmar pinch strength.
Conclusions: Disease activity was associated with hand function impairment in RA patients with variable
follow-up. MHQ discriminated poorer hand function in remission patients who otherwise had similar DASH
scores as the controls did.
Keywords: Musculoskeletal physiological processes, Rheumatoid arthritis, Disease activity
Background
Rheumatoid arthritis (RA) is characterized by symmetric,
polyarticular inflammation of the synovia, typically of the
small joints of the hands, wrists and metatarsophalangeal
joints of the feet [1]. Reports in the literature indicate that
70 % of all RA patients may present with some form of
hand disability at follow-up [2, 3]. Eventually, such
patients will be referred for prophylactic or reconstructive
surgical interventions. However, there is limited evidence-
based research investigating the factors that drive the
surgical decisions for RA [4, 5]. Therefore, it appears
convenient to identify patients with impaired hand func-
tion (HF) or those at risk for impaired HF early in the
disease course and to identify potential predictors.
Although HF may be compromised at follow-up in the
vast majority of RA patients, the current recommenda-
tions for disease assessment are limited to counts of
swollen and tender joints, and these assessments do not
include a comprehensive assessment of HF. Measure-
ment of the grip strength using a dynamometer is a
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performance-based measure of HF that predicts long-
term outcomes in RA patients [6, 7], and by using the
appropriate equipment, grip strength may easily be in-
corporated into routine patient assessments.
Patient-reported outcomes are increasingly recognized
as potentially being more accurate than physician-
reported outcomes and laboratory parameters in predict-
ing long-term disease consequences [8, 9]. Question-
naires included in routine evaluations examine how RA
affects a patient’s physical function and ‘participation’ in
daily activities, and the questionnaires include several
questions pertaining to HF. However, these questions
are usually limited to a few items [7, 10–13]. The
Michigan Hand Outcome Questionnaire (MHQ) mea-
sures an individual’s perception of their hands in
terms of the function, appearance, pain and satisfac-
tion, all of which are reliable and valid measures of
function in RA patients [14, 15]. The Disabilities of
the Arm, Shoulder and Hand Outcome Measure
(DASH) [16] questionnaire is a measure that was
designed for use in single or multiple disorders of the
upper limbs. DASH has demonstrated validity and
reliability as a measure of physical disability in the
upper extremities of RA patients [17, 18], and valid,
reliable normative data are available for use in clinical
and research settings [19].
Hand deformities that compromise HF are typical
features in patients with longstanding and early RA
onset [20, 21]. Impaired HF is prevalent in RA patients
[22], and it correlates with clinical and laboratory
parameters of disease activity [23, 24], patient disability
[22] and hand deformity [24], although these correla-
tions may vary according to the level of disease activity
[25]. In addition, HF tests are sensitive tools for asses-
sing the treatment response [26]. However, routine as-
sessments of RA patients do not include HF evaluations.
In 2004, we initiated an inception cohort of patients with
recent-onset RA; the patients have been prospectively
followed-up to date. In 2014, we performed a comprehen-
sive evaluation of HF in our cohort of patients who were
actively seen at the early arthritis clinic of our institution;
these individuals had variable disease durations and dis-
ease activity. We hypothesized that a significant propor-
tion of our patients could already present with
(undetected) HF impairment, especially those with disease
activity; we additionally aimed to identify the factors that
are associated with impaired HF, with an emphasis on re-
versible factors.
The specific study objectives were as follows:
1. To describe HF in an inception cohort of RA patients
who were classified according to their disease activity
level (disease activity vs. remission) and to compare
the HF of RA patients and healthy controls.
2. To determine the factors associated with impaired
HF, with an emphasis on the disease activity as a
potentially reversible factor.
Methods
Setting and study population
The early arthritis clinic of the Instituto Nacional de
Ciencias Médicas y Nutrición (Mexico) was initiated in
2004. Candidates at the clinic had a disease duration of
<1 year and no specific rheumatic diagnosis other than
RA. Treatment was prescribed by the rheumatologist in
charge of the clinic and was ‘treat to target’ oriented.
Traditional disease-modifying anti-rheumatic drugs
(DMARDs) were used in 99 % of the population, with or
without corticosteroids (up to 50 % of the patients had
corticosteroids during their follow-up). In 2014, when
the study was approved and initiated, 143 patients were
followed at the clinic (19 additional patients were lost to
follow-up and two died) with variable disease duration,
and all were invited to participate in the study. Through
June 2015, 139 patients completed baseline assessments,
and four were excluded for administrative reasons. In
addition, 99 patients underwent a second evaluation that
was performed one year after the baseline assessment.
Standard clinical evaluations performed in the early
arthritis clinic
When patients were enrolled in the clinic, their medical
history and demographic data were recorded, as were
their rheumatoid factor (RF) and antibody to cyclic
citrullinated peptide (ACCP) levels. Follow-up evalua-
tions were scheduled at regular intervals and, at
minimum, always included swollen and tender joint
counts, patient- and physician-reported outcomes, co-
morbidity and treatment assessments. Complete labora-
tory parameters were also determined at follow-ups as
were X-rays of the hands and foot; the latter occurred
on an annual basis [27].
Evaluation of HF
HF was incorporated into the standard evaluations from
2014 onward. A brief interview preceded all testing and
confirmed the absence of significant hand trauma; pa-
tients completed a validated Spanish version of the
MHQ [14] and DASH [16]. Briefly, the MHQ contains
37 items that are distributed into six subscales that
evaluate the overall HF as well as activities of daily liv-
ing, pain, work performance, aesthetics and patient satis-
faction with HF using a five-point ordinal scoring
system. The MHQ takes approximately 15 min to
complete. The scores range from 0 to 100; higher scores
indicate better performance in all domains, except pain.
Normative values are not available. DASH is a 30-item
questionnaire with 21 physical function, six symptom
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and three social role-function items. A six-point ordinal
scale grades the perceived difficulty for each task. The
scale takes approximately 10 min to complete and 5 min
to score, and the scores range from 0 to 100, where 0
represents the optimal HF.
Subsequently, the tip pinch (two points), key pinch
(lateral) and palmar pinch (three-jaw chuck) strengths
were tested first, followed by grip strength. Standardized
arm and hand positions were used as follows. Patients
were seated in a comfortable position with their shoul-
der adducted and neutrally rotated, elbow flexed at 90°,
forearm in neutral, and wrist between 0° and 30° dorsi-
flexion and between 0° and 15° ulnar deviation [28],
(Fig. 1). A device (B&L Engineering®Hand Dynamometer,
B&L Engineering, Santa Anna, CA, USA) was used to
measure their grip strength. For standardization, the
dynamometer was set at the second handle position for
all patients. In addition, the B&L pinch gauge was used
to measure the tip, key and palmar pinch strength, and
scores were read on the needle side of the red readout
marker. For each strength test, three successive mea-
surements were recorded for each (dominant) hand, and
the mean score was calculated. Both instruments were
periodically calibrated during the study. All evaluations
were performed by two previously trained assessors who
were blinded to the rheumatic evaluations but not to the
disease status.
Control population
Sixty-nine healthy Mexican Mestizo adults lacking either
a known medical condition (including disease of the
upper limbs, limiting hand function and significant hand
trauma) or treatment were included; these individuals
comprised the control group. Control status was confirmed
by interview and, when necessary, physical examination.
Controls were matched according to age (±5 years) and
gender because both affect grip strength. Controls were
recruited from the hospital staff, students and patients’
relatives. MHQ and DASH questionnaires, tip pinch, key
pinch, palmar pinch and grip strengths were measured as
described for RA patients.
Ethics
The study was approved by Internal Review Board of the
Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, Mexico. Patients and controls pro-
vided informed written consent to participate in the
study.
Statistical analysis
The distribution of the study variables was examined;
data are presented as the (mean ± SD) for normally
distributed variables and (median, Q25-Q75) for non-
normally distributed variables.
Disease activity was defined according to DAS28 cut-
offs [28]. Remission was defined with a more stringent
criterion (DAS28 < 2.4), and analysis was repeated with
remission defined as DAS28 < 2.6.
The MHQ score was converted into a dichotomous
variable (within normal range/out of normal range)
based on a cut-off obtained as the (mean-2SD) of
control scores. The DASH score was converted to a di-
chotomous variable according to the following: within
the normal range for a score ≤24.78 and outside the
normal range for a score >24.78. This cut-off was estab-
lished based on published normative data for the DASH
questionnaire in a large general population survey [19].
Finally, data from local controls (mean + 2SD) were used
to define values within the normal range for pinch and
grip strengths. Pinch and grip strength analysis were
separately performed for women and men. The analysis
was repeated using normative data for adults [29], and
similar results were obtained.
To achieve objective 1 (comparison of extended HF
between controls, remission patients and patients with
disease activity), multiple comparison post-hoc ANOVA
with Tukey correction analysis was performed. Logistic
regression models were used to establish the factors that
were associated with HF impairment (objective 2).
Variables were selected based on their clinical relevance
and whether they emerged from the model as statisti-
cally significant (p ≤ 0.05) in the univariate analysis
(X2, t Student’s and Mann-Whitney U tests were used
as appropriate). Correlations between variables were
also analyzed; to avoid overfitting the models, the var-
iables included in the final models were based on the
number of outcomes of interest. All statistical tests
Fig. 1 Position for grip strength and pinch measures
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were two-sided and evaluated at the 0.05 significance
level. Statistical analysis was performed using SPSS
version 17.0 (IBM Corporation, USA).
Results
Characteristics of patients and controls
At study entry, RA patients (n = 139) were primarily
middle-age (mean ± SD age, 44.1 ± 13.1 years) females
(n = 124 [89.2 %]) with 11 ± 3.8 years of formal
education, a median disease duration of seven years
(interquartile range [Q25-Q75], 3 to 9 years) and inactive
disease (median DAS28 of 2, [Q25-Q75] 1.3 to 3). One
hundred twenty (86.3 %) patients had RF, 125 (90.6 %) had
ACCP, 55 (39.6 %) had erosive disease and 80 (57.6 %)
were prescribed corticosteroids. All patients were pre-
scribed DMARDs; the median number of DMARDs/pa-
tient was 2 ([Q25-Q75] 1 to 2), and the median number of
comorbidities/patient was 2 ([Q25-Q75] 1 to 3). Of the 69
controls who were evaluated, 62 (89.9 %) were female, and
their mean age was 43.8 ± 11.5 years.
HF evaluation in RA patients with disease activity, with
remission and in controls
There were 91 patients in remission (median DAS28
of 1.5, [Q25-Q75] 1 to 2), 16 with low disease activity
(DAS28 of 2.7, [Q25-Q75] 2.6 to 2.9), 23 with moderate
disease activity (DAS28 of 4.4, [Q25-Q75] 3.7 to 4.7)
and 9 with high disease activity (DAS28 of 6.3, [Q25-Q75]
5.8 to 6.8).
As expected, controls had significantly better scores
than did patients with disease activity (low, moderate
and high). However, RA patients in remission
(DAS28 < 2.4) had similar DASH score and key pinch
strength values as did the controls, but the RA
patients in remission had worse MHQ scores and
impaired grip, tip pinch and palmar pinch strengths
(p < 0.005 for all comparisons) (Table 1).
Differences in the MHQ domains between RA patients
in remission and controls were further explored. As
shown in Table 2, there were significant differences
between the groups in five of the six MHQ domains:
overall HF, pain, work performance, aesthetics and
satisfaction.
Factors associated with impaired HF
According to MHQ
MHQ was considered to be within the normal range
(MHQ-NR) for scores ≥84. Accordingly, 76 (54.7.3 %)
patients had an MHQ-NR and 63 (45.3 %) did not.
Patients in the former group had a lower DAS28 and
fewer DMARDs/patient; they frequently tended to be
male, younger and more educated and had a longer
disease duration (Table 3). The logistic regression models
that were used to identify the factors associated with
MHQ-NR included the following variables: DAS28 and
number of DMARDs/patient (low correlated with DAS28:
rho = 0.36; p ≤ 0.001). DAS28 was the only factor
associated with an MHQ score outside the normal
range (β coefficient = 2.58 [95 % CI 1.79 to 3.73];
p ≤ 0.001; R2 = 0.358).
According to DASH
One hundred fourteen (82 %) patients had a DASH-
NR score >24.78, and 25 (18 %) did not. Patients
from the former group were younger, had a longer
disease duration, had a lower DAS28 and had fewer
DMARDs/patient (Table 3). Logistic regression models
that included the above-described variables showed
that DAS28 (β coefficient = 4.08 [95 % CI 2.34 to
7.12]; p ≤ 0.001) and age (β coefficient = 1.08 [95 % CI
1.03 to 1.147]; p = 0.005) were associated with a
DASH score out of the normal range (R2 = 0.612).
According to the pinch and grip strength
Impaired pinch and grip strengths were defined as
follows, for women and men, respectively: tip pinch as
<2.4 kg and <2.5 kg; palmar pinch as <3.4 kg and
<2.9 kg; key pinch as <4.4 kg and <5.7 kg; and grip
strength as <11.5 kg and <15.7 kg, respectively. The
number of RA patients (women and men) with values
outside the normal range for tip, palmar and key pinch
and grip strengths were as follows: 26 (21 %) and 0; 34
(27.4 %) and 0; 32 (25.8 %) and 0; and 39 (31.5 %) and 2
(13.3 %), respectively.
A comparison between patients with/without impaired
pinch and grip strengths was performed. Due to the
limited number of men assessed, only data from the
female population are presented. Variables with signifi-
cant differences included (data not shown) DAS28 for
tip, key and palmar pinch strengths and DAS28 with
comorbidity/patient for grip strength.
Table 1 HF evaluation in controls, patients in remission and




remission (N = 91)
Patients with disease
activity (N = 48)
MHQ 98.9 (95.5–100) 92.5 (83.3–97.7)* 65 (54.5–82.4)*
DASH 0 (0–1) 0.8 (0–6.7) 22.5 (5.4–41.5)*
Grip strengthb 22.3 (19.1–26.5) 18.7 (13.7–23)* 10.7 (7.5–15.3)*
Tip pinchb 4.5 (3.9–5.4) 3.8 (3.2–4.5)* 3 (2.2–3.3)*
Key pinchb 7.1 (6–8) 6.3 (5.3–7.3) 4.8 (3.7–5.8)*
Palmar pinchb 6 (4.9–7) 5 (4–6.2)* 3.7 (2.5–4.6)*
MHQ Michigan hand outcome questionnaire, DASH Disabilities of the arm,
shoulder and hand outcome measure
*p ≤ 0.005 vs. controls
aData are presented as the median (Q25-Q75)
bKg
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Finally, different regression models were tested. Table 4
summarizes the most significant findings in the female
subpopulation (N = 124). Higher DAS28 was consistently
associated with impaired pinch and grip strengths; the
only additional factor associated with impaired grip
strength was the number of comorbidities/patient.
Receiver operating characteristic (ROC) curve analysis
was performed to define the optimal cut-off for DAS28
to predict the MHQ-NR, DASH-NR, and pinch and grip
strength values within NR (Fig. 2). DAS28 cut-offs varied
from 2 to 2.9, depending on the selected outcome.
Disease activity and impaired HF
To further test the association between DAS28 and
HF impairment, data from 99 patients who had an
additional one year of follow-up assessments were
analyzed. Of these, 53 (53.5 %) patients maintained
the same disease activity level, 21 (21.2 %) improved
and 25 (25.5 %) deteriorated. The changes in DAS28
correlated with the changes in MHQ (rho = −0.53),
DASH (rho = 0.50), grip strength (rho = −0.55), tip
pinch strength (rho = −0.34) and key pinch strength
(rho = −0.63) (p ≤ 0.01 for all comparisons) (Fig. 3).
Discussion
The present study was performed within an ongoing
cohort of early-onset RA patients, who were highly rep-
resented by middle-age women with a median of seven
years of disease duration and different disease activity
levels. In addition to standardized rheumatic assess-
ments, patients underwent an extensive HF evaluation
that combined self-assessments and direct measure-
ments of grip and pinch strengths. Similar combinations
have been proposed as the most reliable evaluation of an
individual’s functional capacity.
Disease activity evaluated according to DAS28 was
the most consistent factor associated with impaired
HF. The results were further confirmed in patients
with prospective one-year assessments. Johnsson et al.
[20] longitudinally assessed hand deformities in an
early onset RA cohort and found that patients with
deformities experienced more disease activity during
the first five years. Although we did not evaluate
hand deformities, they have been shown to affect
both HF and general function [22, 23]. Additional
studies have associated disease activity with the grip
force, HF and functional abilities [25, 30, 31]. Inter-
estingly, the DAS28 cut-offs for predicting HF
Table 2 Comparison of the MHQ domains between controls and RA patients in remission
Overall hand Functiona Activities of Daily livinga Paina Worka Aestheticsa Satisfactiona
Controls 100 (98–100) 100 (100–100) 0 (0–0) 100 (100–100) 100 (93.8–100) 100 (94–100)
Patients in remission 95 (75–100)* 100 (100–100) 10 (0–30)* 100 (95–100)* 93.8 (75–100)* 91.7 (75–199)*
Data are presented as the median (Q25-Q75)
MHQ Michigan hand outcome questionnaire
*p ≤ 0.05
aMHQ domains
Table 3 Comparison of the demographic and disease characteristics between RA patients with/without HF within the normal range
according to patient-reported outcomes (MHQ and DASH)
Characteristics MHQ-NR, N = 76 MHQ below NR, N = 63 DASH-NR, N = 114 DASH above NR, N = 25 p1/p2
Female gender, N° (%) 65 (85.5) 59 (93.7) 99 (86.8) 25 (100) 0.17/0.07
Age at hand function evaluationa 42.7 ± 12.6 45.7 ± 13.6 42.5 ± 13.4 51.2 ± 8.8 0.18/0.002
Years of scholarshipa 11.4 ± 3.6 10.5 ± 4 11.2 ± 3.7 10.1 ± 4.4 0.15/0.19
Disease duration, yearsb 7.5 (3–10) 6 (2–9) 7 (3–10) 4 (0–8) 0.17/0.007
N° (%) of patients with RF 63 (82.9) 57 (90.5) 97 (85.1) 23 (92) 0.22/0.53
N° (%) of patients with ACCP 69 (90.8) 56 (90.3) 102 (90.3) 23 (92) 1/1
DAS28b 1.5 (1–2.1) 3 (1.8–4.5) 1.7 (1.1–2.4) 4.4 (3–6) 0.000/0.00
N° (%) of patients with erosions 29 (38.2) 26 (41.3) 46 (40.4) 9 (36) 0.73/0.82
N° of comorbidities/patientb 2 (1–3) 1 (1–3) 2 (1–3) 2 (1–4) 0.55/0.56
N° (%) of patients with corticosteroids 41 (53.9) 39 (61.9) 64 (56.1) 16 (64) 0.39/0.51
N° of DMARDs/patientb 1 (1–2) 2 (2–2) 2 (1–2) 2 (2–2) 0.000/0.02
RF rheumatoid factor, ACCP antibodies to cyclic citrullinated peptides, MHQ Michigan Hand Outcome Questionnaire, DASH Disabilities of the Arm, Shoulder and
Hand Outcome Measure, NR normal range, p1 MHQ-NR score vs. MHQ score below NR, and p2 DASH-NR score vs. DASH score above NR
aMean ± SD
bMedian (Q25-Q75)
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impairment varied from 2.0 to 2.9, and they were
generally below the DAS28 remission criterion that is
most frequently used in clinical practice [32]. Our re-
sults support concerns raised against the DAS28 cut-
off remission criterion, which overestimates true re-
mission. DAS28 is a composite index that is widely
used in clinical practice; however, patients in DAS28-
remission do not necessarily perceive themselves as
having HF within the normal range.
Age was the only additional (to DAS28) factor
associated with HF impairment when it was evaluated
according to DASH in the entire population. As
described in the general population, older age is also
associated (albeit inconsistently) with a more severe
disease pattern and physical disability in RA patients
[33, 34]. In our study, older age had a subtle impact
on the DASH score. The number of comorbidity/patient
was also associated with impaired grip strength,
although the impact of DAS28 was stronger. These
results were limited to the female population because
there were few RA male patients with grip and pinch
strengths within the normal range. There is strong
evidence that the presence of comorbidities influences
the outcome measures for the RA activity and severity;
disease activity is usually assessed via composite indices,
which include items influenced by concomitant disease
[27, 35–37]. Additionally, in different populations, depres-
sion and other comorbid conditions are associated with
worse patient-rated hand function [38, 39].
As expected, the present study showed that RA
patients exhibited HF impairment compared with
controls. Interestingly, RA patients in DAS28-remission
had physical function (as per HAQ, data not shown) and
HF similar to controls when evaluated according to
DASH and key pinch strength. Our patients in remission
did not achieve “control norms” when they were evaluated
according to the MHQ. The MHQ is a patient-oriented
questionnaire that covers HF problems, and it is
particularly suitable for evaluating the rheumatoid
hand [14]. We recommend that it be included in the
RA patient evaluation because it may identify HF
Table 4 Logistic regression models associated with impaired





















CI Confidence interval; all p ≤ 0.001
a95%CI
Fig. 2 ROC curves: cut-off for DAS 28 to predict the MHQ-NR and DASH-NR scores, pinch and grip strength values within normal ranges
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impairment in individuals who otherwise achieve popula-
tion norms for health-related quality-of-life outcomes.
The limitations of the present study should be addressed.
First, we performed an extended HF evaluation without
including the complete International Classification of
Functioning, Disability and Health (ICF) comprehen-
sive core set for the measures developed for RA [40].
Second, we did not account for hand dominance
when scoring the grip and pinch strengths, although
studies have recommended ignoring this issue due to
the small percentage (<10 %) of left-hand dominant
subjects [29]. Third, HF assessments were performed
by two differently trained physicians; we did not
formally assess their agreement or reliability. Fourth,
assessors were not blinded to the disease/control
status and there could be bias in measures of grip
and pinch strength. Fifth, we included a modest num-
ber of healthy controls from whom normative data
were obtained. Sixth, we investigated a limited num-
ber of factors associated with HF impairment. Finally,
our population only included a few men and our
results may not be generalized to males.
Conclusions
A comprehensive evaluation of HF in RA patients
should be encouraged. Disease activity was the most
consistent factor associated with impaired HF. We rec-
ommend including physical measures as well as patient
reported-outcomes in the routine evaluation of HF in
RA patients. RA patients who are in remission may
present with HF that is similar to controls. In this re-
gard, the MHQ preferentially identified HF impairment
instead of patients in remission in whom the additional
patient-reported measures were within the normal levels.
Abbreviation
ACCP: Antibodies to cyclic citrullinated peptides; ANOVA: One-way analysis of
variance; CI: Confidence interval; DAS28: Disease activity score for 28 evaluated
joints; DASH: The disabilities of the arm, shoulder and hand outcome measure;
DMARDs: Disease modifying anti-rheumatic drugs; HDA: High disease activity;
HF: Hand function; ICF: International classification of functioning, disability and
health; LDA: Low disease activity; MDA: Moderate disease activity; MHQ: The
Michigan hand outcome questionnaire; NR: Normal range; RA: Rheumatoid
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